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Evaluation of a rapid immunochromatographic ODK0501 assay for detecting 
Streptococcus pneumoniae antigen in sputum from patients with lower respiratory 
tract infection 
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A novel, rapid and noninvasive test (ODK0501) to detect Streptococcus pneumoniae 
antigen was evaluated in a Japanese multicenter study. ODK0501 uses polyclonal 
antibodies to detect C-polysaccharide of S. pneumoniae from sputum by an 
immunochromatographic assay. The utility of ODK0501 was evaluated in 161 adult 
patients with lower respiratory tract infection between March 2006 and March 2007. 
Bacterial culture and identification, real-time PCR, and ODK0501 assays were 
performed on sputum samples, and Binax NOW Streptococcus pneumoniae antigen test 
was performed in urine samples obtained from the same patients. The performance of 
all tests was compared based on the results of bacterial culture and identification. The 
sensitivity and specificity of ODK0501 were 89.1% (49/55) and 95.3% (101/106), 
respectively. We then compared the Binax NOW Streptococcus pneumoniae antigen test 
with ODK0501 in samples from 142 patients. The sensitivity of ODK0501 and the 
Binax NOW S. pneumoniae antigen test was 90.0% (45/50) and 62.0% (31/50), 
respectively (P = 0.002). The relative quantity of S. pneumoniae in expectorated sputum 
was calculated using real-time PCR and indicated that the possibility of false-positive 
results of ODK0501 due to indigenous S. pneumoniae was low. The positive and 
negative concordance rates of ODK0501 and Binax NOW were 96.8% (30/31) and 
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21.1% (4/19), respectively. Binax NOW was less capable of detecting S. pneumoniae 
antigen among patients with underlying COPD. In conclusion, ODK0501 is 




Streptococcus pneumoniae is a frequent cause of community-acquired bacterial 
pneumonia and lower respiratory tract infection (10, 11, 19, 21), and a major cause of 
significant morbidity and mortality in Japan and the rest of the world (5). 
Since pneumococcal infections are common and can be severe, appropriate initial 
selection of antimicrobial agents is crucial to an optimal outcome. Rapid and precise 
identification of the causative agents of infectious diseases is critical but challenging. 
Pathogen-oriented, prompt selection and application of antimicrobial agents improves 
prognosis, reduces medical costs and prevents the development of drug-resistant 
bacteria due to their inappropriate use. The gold standard, bacterial culture to identify 
causative microorganisms requires several days to yield result, and is thus unhelpful to 
the initial selection of appropriate antibacterial drugs. Although Gleckman et al. 
reported that classic Gram staining of sputum, which is simple and inexpensive, is 
useful in the diagnosis of bacterial infections (7), Reed and others found that it is 
ineffective for rapid diagnoses (6, 18). In addition, staining results rely on several 
factors such as the quality of the sputum samples and the skill of laboratory personnel in 
processing samples (7). Thus, Gram staining is not recommended for all patients with 
community-acquired pneumonia according to the most recent “Infectious Diseases 
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Society of America/American Thoracic Society (IDSA/ATS) Consensus Guidelines on 
the Management of Community-Acquired Pneumonia in Adults” (12).  
Urinary antigen detection is an alternative rapid diagnostic technique for detecting 
antigens of S. pneumoniae and Legionella pneumophila as respiratory pathogens. The 
Binax NOW Streptococcus pneumoniae urinary antigen test (Binax NOW; Binax, Inc., 
Portland, ME) detects cell wall antigens secreted in urine using an 
immunochromatographic method to separate capsular polysaccharides (C-ps) of S. 
pneumoniae. The test is noninvasive, rapid (the entire assay can be completed in about 
15 minutes) and the specificity and sensitivity of detecting pneumococcal infections in 
adult patients is > 90% and 50% to 80%, respectively, which allows early diagnosis (3, 
8, 16). Moreover, even when S. pneumoniae cannot be identified by bacterial culture 
tests after starting antibiotic therapy, the assay can still detect this organism. However, 
Binax NOW has significant problems including false-positive results due to indigenous 
S. pneumoniae in children (17) and antigens can be detected even one to three months 
after treatment (13, 14).  
The ODK0501 (Otsuka Pharmaceutical Co., Ltd. Tokyo, Japan) is a diagnostic kit that 
uses polyclonal antibodies to detect anti-pneumococcal C-ps, a cell wall antigen of S. 
pneumoniae (4). This immunochromatographic method is rapid, noninvasive and 
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analyzes sputum derived directly from a local infection site. Here, we evaluated the 
ability ODK0501 to detect S. pneumoniae among patients with lower respiratory tract 
infection at several Japanese medical institutions and compared its performance with 
that of Binax NOW. The goal of this study is to prove the usefulness of ODK0501 and 
to its performance in clinical settings. 
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MATERIALS AND METHODS 
Study settings  
This case control study proceeded between March 2006 and March 2007 at the 
following 14 medical institutions in Japan: the Nagasaki University School of Medicine, 
Saitama Cardiovascular and Respiratory Center, the National Hospital Organization 
Ureshino Medical Center, Isahaya Health Insurance General Hospital, Hokusho Central 
Hospital, Japanese Red Cross Nagasaki Genbaku Isahaya Hospital, Kurashiki Central 
Hospital, Sasebo City General Hospital, Toranomon Hospital, Nakahama Clinic, 
Ohmichi Internal and Respiratory Medicine, Kitakyushu Municipal Yahata Hospital, 
University of Tokushima School of Medicine and Shinrakuen Hospital. This study was 
approved by the Institutional Review Board of each medical institute and the informed 
consent was obtained from each subject. 
All adult inpatients or outpatients (age,  15 years) with signs of lower respiratory 
infections including pneumonia and who had undergone sputum exploration were 
eligible for inclusion in this study. Prior antibiotics use was not a criterion for exclusion. 
Patients with a provisional diagnosis of lower respiratory infections were assessed by 
each study investigator to confirm the diagnosis. Clinical information such as existing 
underlying diseases, prior antibiotics use, number of days from onset until the day when 
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assays were performed, white blood cell (WBC) counts and C-reactive protein (CRP) 
levels were recorded when the patients registered and retrospectively analyzed. 
 
Sample collection and microbiological investigations 
Single expectorated sputum and urine samples were collected from patients who had 
provided written, informed consent to participate in this study either at a hospital visit or 
at the time of a presumptive diagnosis of lower respiratory infection. All expectorated 
sputum samples were conventionally Gram stained and transferred to the microbiology 
laboratory at Hokusho Central Hospital for expert evaluation. Sputum samples were 
also cultured at 37°C for 24 hours on blood and chocolate agar at each institution. 
Presumptive colonies of bacteria were picked up and identified by biochemical testing. 
Some portions of the expectorated sputum samples were placed in different containers 
at the time of sampling, and stored at -20°C until assay with real-time PCR to detect and 
quantify S. pneumoniae. 
Samples were immediately evaluated using ODK0501 and Binax NOW, otherwise, 
stored at 4°C until next available day to perform these tests (all assays were performed 
within 48 hours after collection of samples). 
 Soluble Legionella pneumophila serogroup 1 antigen in urine was investigated using 
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another immunochromatographic assay and antibodies against Mycoplasma pneumoniae, 
Chlamydophila psittaci and C. pneumoniae were examined using complement fixation 
tests. 
 
Measurement and interpretation of results obtained with ODK0501 and Binax 
NOW  
Each of the participating institutions followed the procedures indicated below.  
Sputum samples collected on swabs from containers were shaken in tubes containing 
sample extract and left for 5 minutes. Swab tips were removed from the tubes while 
squeezing, a filter was placed on the tube, and the extract was dropped onto the 
ODK0501 instrument. Approximately 20 minutes later, a positive test result was 
indicated by the presence of one red test line and one control lines (two lines), whereas 
a negative result was indicated by the appearance of only the control line. 
Results obtained using Binax NOW were measured and interpreted at the each of 
institutions in accordance with the instructions provided by the manufacturer (3). 
 
Criteria for etiological diagnosis 
 We evaluated only qualified samples defined according to standard criteria (presence 
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of > 25 WBC and < 25 squamous cells per low-power magnification field [× 100]). The 
following criteria were used to classify a case of lower respiratory infections as being of 
known etiology: (ⅰ) M. pneumoniae C. psittaci and C. pneumoniae, a  4-fold increase 
in antibody, as determined by the complement fixation test; (ⅱ) Legionella antigen 
detected in urine, (ⅲ ) for S. pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Staphylococcus aureus and other bacteria including gram-negative 
enterobacteria, isolation of the pathogen of the predominant organism from a qualified 
sputum sample. Patients who did not fulfill the etiologic diagnostic criteria described 
above were considered to have lower respiratory infection of unknown etiology. 
 
Real-time PCR for pneumococcal surface protein A (Psp A) gene quantitation in 
expectorated sputum samples 
We extracted DNA from expectorated sputum samples using the QIAamp® DNA Mini 
Kit (Qiagen, Valencia, CA) and the relative amount of S. pneumoniae was quantified by 
real-time PCR using a primer and TaqMan probe established for the region of the Psp A 
gene (2, 22) of S. pneumoniae (Table 1). Real-time PCR proceeded on an ABI7700 or 
ABI7900 (Applied Biosystems, Foster City, CA) at Kitazato-Otsuka Biomedical Assay 
Laboratory, Kanagawa, Japan and sequences were analyzed using Sequence Detector V. 
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1.7a, V.2.2.2 SDS (Applied Biosystems, Foster City, CA). RNase free water and the 
extracted DNA from S. pneumoniae ATCC6303 were used for negative and positive 
control, respectively. After initial denaturation at 95°C for 15 minutes, PCR products 
were amplified by 50 cycles of 15 seconds at 94°C and 1 minute at 60°C. Copy 
numbers of the Psp A gene were calculated and compared among ODK0501- and 
culture-positive and -negative sputum samples.  
 
Statistical analysis 
The sensitivity and specificity based on the results of the sputum cultures of ODK0501 
and Binax NOW was compared using Fisher's exact probability test (two-tailed, level of 
significant difference P < 0.05). Characteristics of patients with pneumococcal infection 
diagnosed by both culture and ODK0501 as positive were also compared with Binax 
NOW-positive or -negative arms. We compared the proportions of qualitative variables 
using Fisher's exact test, and applied the Mann-Whitney-U test for quantitative variables. 
Relationships between the results obtained from real-time PCR for relative amounts of S. 




Composition of patients and etiological agents identified from patients with lower 
respiratory tract infection 
Of the 246 patients exhibiting signs and symptoms compatible with lower respiratory 
infection, 85 were excluded due to poor sputum quality (presence of either or both of < 
25 WBC and > 25 squamous cells per low-power magnification field [× 100]).  
We thus investigated samples from 161 inpatients and outpatients (109 males: age range, 
22 to 92 y; median age, 71.0 y, 52 females: age range, 15 to 96 y; median age, 65.5 y) 
with lower respiratory tract infection. Table 2 shows the clinical status of the patients. 
Most had pneumonia (79.5%), followed by acute exacerbation of chronic obstructive 
pulmonary disease (AECOPD) (7.5%), acute bronchitis (6.2%), bronchiectasis (5.0%), 
chronic bronchitis (1.2%) and only one had a lung abscess. We examined samples from 
161 and 142 patients using ODK0501 and Binax NOW, respectively. Table 2 also shows 
the etiological agents. According to conventional microbiological criteria, etiological 
agents were identified in 106 patients (65.8%). The following were detected and 
determined as causative agents: S. pneumoniae in 55 (34.2%), Haemophilus influenzae 
in 25 (15.5%), M. pneumoniae in 5 (3.1%), Staphylococcus aureus in 8 (5.0%), 
Pseudomonas aeruginosa in 7 (4.3%), Moraxella catarrhalis in 5 (3.1%), and 
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Klebsiella pneumoniae in 2 (1.2%). Four patients with mixed S. pneumoniae and H. 
influenzae infection were in the pneumonia and AECOPD groups. Two other patients in 
the pneumonia group had mixed infection due to S. pneumoniae and C. pneumoniae, 
and to M. pneumoniae and P. aeruginosa. The microbial etiology remained unknown 
after conventional microbiological culture and antibody test in 55 (34.2%) of the 161 
patients. 
 
Overall sensitivity and specificity of ODK0501  
The ODK0501 results were positive in 54 of 161 patients (33.5%). Table 2 shows the 
distribution of ODK0501 positivity in each patient group. ODK0501 was positive in 41 
(87.2%) of 47 patients with pneumococcal pneumonia including four patients with 
mixed infections and in all patients with AECOPD (n = 4), acute bronchitis (n = 1), 
bronchiectasis (n = 1) and chronic bronchitis (n = 1) caused by S. pneumoniae. The test 
sensitivity was 89.1% (49/55), the specificity was 95.3% (101/106) and the positive and 
negative predictive values were 90.7% and 94.4%, respectively, based on the results of 
the sputum cultures.  
 
Comparison of sensitivity and specificity between ODK0501 and Binax NOW  
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We compared the sensitivity and specificity between ODK0501 and Binax NOW 
against sputum culture results from 142 of the 161 patients (Binax NOW was not 
performed in 19 of 161 patients). 
The ODK0501 test sensitivity was 90.0% (45/50), the specificity was 95.7% (88/92) 
and the positive and negative predictive values were 91.8% and 94.6%, respectively, 
based on the sputum cultures. The Binax NOW test sensitivity was 62.0% (31/50), the 
specificity was 96.7% (89/92) and the positive and negative predictive values were 
91.2% and 82.4%, respectively, based on the sputum cultures. Specificity did not 
significantly differ between the two tests, but the sensitivity of ODK0501 for detecting 
S. pneumoniae was significantly higher (P = 0.002). 
 
Quantification of Psp A gene in sputum by real-time PCR  
We applied real-time PCR to detect and quantify the relative amount of S. pneumoniae 
in expectorated sputum samples from 161 patients with lower respiratory tract infection. 
Figure 1 shows that Psp A gene copy numbers were higher among the 
ODK0501-positive and culture-positive population. The population that was both 
ODK0501- and culture-negative was distributed in the lower copy number of the Psp A 
gene in sputum. The copy numbers of the Psp A gene significantly differed among 
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ODK0501-positive and -negative populations (P < 0.001). 
 
False-positive and false-negative ODK0501 results among patients with lower 
respiratory infection  
 Table 3 summarizes the clinical and laboratory data of the five S. pneumoniae 
culture-negative patients with lower respiratory infection and apparent false-positive 
ODK0501 results. Binax NOW was positive and the Psp A gene copy number was > 6 × 
106 in same two patients (Patients 2 and 4). 
 Table 4 summarizes the clinical and laboratory data from 6 patients with lower 
respiratory infection who generated false-negative results on ODK0501 but were 
positive in S. pneumoniae cultures. All of these patients had pneumonia and Binax 
NOW was positive in only one of them (Patient 3). All of these patients had > 1 × 105 
copies of the Psp A gene.  
 
Comparison between ODK0501 and Binax NOW among patients with 
pneumococcal infections  
We compared the performance of ODK0501 and Binax NOW among 50 patients with 
pneumococcal infection. Five of 55 pneumococcal patients were excluded due to the 
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absence of Binax NOW data. The positive and negative concordance rates of ODK0501 
and Binax NOW were 96.8% (30/31) and 21.1% (4/19), respectively.  
Fifteen patients were ODK0501 positive and Binax NOW negative. Table 5 
summarizes their clinical and laboratory findings of ODK0501-positive population 
among pneumococcal infection proved by culture test. Age, gender, final diagnosis, 
underlying disease, prior antibiotics use, WBC count, CRP level, copy numbers of Psp 
A gene and days from onset until assay did not significantly differ between Binax 
NOW-positive and -negative populations. However, the ODK0501-positive and Binax 
NOW-negative population contained statistically more patients with COPD than the 
population that was positive in both tests (P=0.016). Only Patient 3 was ODK0501 
negative and Binax NOW positive (Table 4).   
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  DISCUSSION 
Although early diagnosis and antimicrobial drug administration comprise the basic 
principles of treating pneumococcal as well as other infections, the causative agents 
may not be correctly identified in many patients at the start of therapy. 
Binax NOW is commercially available and widely used in clinical settings, but it 
possess some disadvantages including false-positive results due to indigenous S. 
pneumoniae (17), lasting positivity even 1 - 3 months after treatment (13, 14) and no 
indication for anuric patients. Furthermore, the test has a variable and relatively low 
sensitivity of 50 to 80% (3, 8, 16). The novel ODK0501 tests sputum samples derived 
directly from inflammatory sites using polyclonal antibodies to detect 
anti-pneumococcal C-ps (20), a common cell wall antigen of S. pneumoniae (4). Thus, 
all types of S. pneumoniae can be detected regardless of capsule serotype.  
The present clinical study evaluated the applicability of ODK0501 and compared with 
Binax NOW in adult patients (age,  15 years). The most frequent isolate in the present 
study was S. pneumoniae (34.7%) followed by H. influenza among 161 patients with 
lower respiratory tract infection. These findings indicated that the frequency of major 
isolated bacteria from patients with lower respiratory tract infection was similar to those 
of other studies, and thus our patient population was valid for analysis.  
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ODK0501 yielded favorable results including sensitivity and specificity of 89.1% and 
95.3%, respectively, based on sputum culture results from 161 patients. Even when 
analyzed a total of 120 cases with more superior quality of expectorated sputum 
(presence of both of > 25 WBC and < 10 squamous cells per low-power magnification 
field [× 100]) (data not shown), the result showed that higher sensitivity (92.9 %) and 
almost equal specificity (93.6 %). The sensitivity (87.2%) and specificity (95.1%) was 
also favorable when evaluated among 128 pneumonia cases only.  
The sensitivity of ODK0501 was significantly higher (P = 0.002) and the specificity 
was >95% when compared with Binax NOW. The negative predictive value of Binax 
NOW was also lower than that of ODK0501. These data indicated ODK0501 is superior 
to Binax NOW. However, because S. pneumoniae can be indigenous to the nasal cavity, 
nasopharyngeal and intraoral regions of some of the elderly, infants and children (1, 9) 
sputum or nasopharyngeal samples obtained from such individuals might be S. 
pneumoniae-positive with ODK0501. The question will be raised that the higher 
sensitivity of ODK0501 suggests that indigenous, colonizing S. pneumoniae in the 
respiratory tract detected by this method will be considered as the cause of infection and 
lead to over diagnosis. To answer this question, we measured amounts of S. pneumoniae 
in expectorated sputum. Psp A has being originally considered as a potential antigen and 
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virulence factor of S. pneumoniae (15) and was recently applied for epidemiological 
analysis of S. pneumoniae infection (2). Since single copy of Psp A gene exist per S. 
pneumoniae cell and the copy number in sputum relatively correlated to the numbers of 
S. pneumoniae cells (data not shown), we evaluated Psp A gene copy numbers in 
sputum using real-time PCR. The PCR data were then substituted as relative amounts of 
S. pneumoniae in sputum samples. However, because the amounts of sputum samples 
varied, values were corrected using human DNA concentrations in the sputum, and 
copies/μg DNA (calculated based on human DNA concentrations in sputum) was used 
as the units of measurement. The result for quantitative cultures using an adjusted 
bacterial suspension as the measurement sample of 9.45 × 105 CFU/mL was nearly 
equivalent to 4.3 × 105 copies/μg DNA, indicating a nearly 1:1 relationship (data not 
shown). Most ODK0501-negative patients also had negative culture results as well as 
less S. pneumoniae. Hence, ODK0501-positive patients also had positive culture results 
and more S. pneumoniae according to real-time PCR. These data suggested that 
ODK0501 does not detect low amount of S. pneumoniae, which translates as a low 
false-positive rate in the presence of indigenous S. pneumoniae. Real-time PCR data 
also supported the finding that the analytical sensitivity of ODK0501 that was 
approximately 104 CFU/ml in the development phase (4) was appropriate to detect S. 
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pneumoniae as the cause of lower respiratory infection.  
Analysis of the clinical characteristics of five ODK0501 false-positive patients 
revealed no specific factors that could account for this result. However, Binax NOW 
was positive in two patients in whom we detected 6 × 106 copies of the Psp A gene, 
suggesting that culture did not detect S. pneumoniae for reasons that remain unknown. 
The severity of pneumonia among the 5 patients scored as defined in the “The Japanese 
Respiratory Society Guidelines for the Management of Community–Acquired 
Pneumonia in Adults” did not differ (data not shown).  
Six patients were ODK0501 false-negative and their clinical backgrounds also did not 
offer any apparent explanations. Only one patient was Binax NOW-positive, but 4 were 
Binax NOW negative, indicating that Binax NOW does not offer any advantages as a 
rapid diagnostic tool for pneumococcal infection. 
Among the 50 patients with S. pneumoniae infection diagnosed by culture, 15 (30.0%) 
were Binax NOW-negative and ODK0501-positive, indicating that ODK0501 possess 
more power to detect S. pneumoniae antigen than Binax NOW. We investigated which 
clinical factors were related to the higher sensitivity of ODK0501 in diagnosing 
pneumococcal infections. We compared the clinical backgrounds of ODK0501- positive 
and the Binax NOW-positive arm, and the ODK0501-positive and Binax 
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NOW-negative arm. We found that only underlying COPD statistically differed among 
all tested factors, though the number of COPD cases was only thirteen. In these COPD 
patients, age, prior antibiotics use, WBC count, CRP level, copy numbers of Psp A gene 
and days from onset until assay were compared and no significant differences between 
Binax-positive and –negative populations were found (data not shown). Although 
whether the detection rate of Binax NOW decreases in COPD patients remains 
unknown, ODK0501 was more sensitive in the present study.  
The relationships between the severity of pneumonia and the sensitivity of ODK0501 
and Binax NOW are also important. We compared the performance of ODK0501 and 
Binax NOW with the severity of pneumonia scored according to the definitions in the 
“The Japanese Respiratory Society Guidelines for the Management of 
Community-Acquired Pneumonia in Adults” among patients with community-acquired 
pneumonia and found no significant differences between the detection rates of 
pneumococcal pneumonia at any level of severity between the two assays (data not 
shown). 
In conclusion, since ODK0501 evaluates sputum sampled from local sites of infection, 
the results reflect the real-time status of infection due to S. pneumoniae. Our study 
indicated ODK0501 was statistically more sensitive than the Binax NOW Streptococcus 
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pneumoniae urinary antigen test, suggesting that ODK0501will significantly contribute 
to the early, rapid and non-invasive diagnosis of pneumococcal infection in adult. 
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TABLE 1. Primers used for real-time PCR for quantification of Streptococcus 
pneumoniae. 
Forward primer 5’-CAAGTCTAGCCAGCGTCGCTAT-3’ 







TABLE 2. The patient condition group and ability of ODK0501 to detect Streptococcus 
pneumoniae. 




Ratio (%) of ODK0501+ 
patients/total patients 
Pneumonia 128(79.5)  
 Streptococcus pneumoniae  37/43 (86.0)
 Haemophilus influenzae  1/16 (6.3)
 S. pneumoniae and H. influenzae  3/3 (100.0)
 Staphylococcus aureus  0/7 
 Moraxella catarrhalis  0/3 
 Pseudomonas aeruginosa  0/3 
 Klebsiella pneumoniae  0/2 
 Streptococcus milleri group  0/1 
 Mycoplasma pneumoniae  0/4 
 Aspergillus spp.  0/1 
 Legionella pneumophila  0/1 
 Chlamydophila psittaci  0/1 
 S. pneumoniae and C. pneumoniae  1/1 (100.0)
 M. pneumoniae and P. aeruginosa  0/1 
 Pathogen not identified  3/41 (7.3)
Acute exacerbation of chronic obstructive 
pulmonary disease 
12 (7.5)  
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 S. pneumoniae  4/4 (100.0)
 H. influnezae  0/2 
 S. pneumoniae and H. influenzae  1/1 (100.0)
 M. catarrhalis  0/2 
 Pathogen not identified  0/3 
Acute bronchitis 10 (6.2)  
 H. influnezae  0/2 
 S. pneumoniae  1/1 (100.0)
 S. aureus  0/1 
 Pathogen not identified  0/6 
Bronchiectasis 8 (5.0)  
 P. aeruginosa  0/3 
 S. pneumoniae  1/1 (100.0)
 Pathogen not identified  0/4 
Chronic bronchitis 2 (1.2)  
 S. pneumoniae  1/1 (100.0)
 Pathogen not identified  1/1 (100.0)
Lung abscess 1 (0.6)  
 H. influnezae  0/1 
Total 161 54/161 
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TABLE 3. Summary of clinical and laboratory data for ODK0501 false-positive patients. 













Time from symptom onset 
until assay performance 
(days) 
1 Pneumonia M, 43 Bronchial asthma None NDd － 2×106 4 
2 Pneumonia M, 79 COPD SBT/ABPCa; CAMb Aspergillus spp. + 6×106 1 
3 Pneumonia M, 62 Bronchiectasis None 
Haemophilus 
influnezae 
－ 7×102 2 




F, 50 None None Mixed oral flora － 1×104 3 
a SBT/ABPC, sulbactam/ampicillin; b CAM, clarithromycin; c CTM-HE, cefotiam hexetil; d ND, not detectable. 
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TABLE 4. Summary of clinical and laboratory data for ODK0501 false-negative patients.  
 


















Time from symptom onset 
until assay performance (days) 
1 Pneumonia M, 28 None None + － 6×106 1 
2 Pneumonia M, 65 COPD None － － 1×106 3 
3 Pneumonia M, 33 None CAMb;CAZc + + 9×106 5 
4 Pneumonia F, 33 None None － － 5×105 2 
5 Pneumonia M, 42 Interstitial pneumonia SBTPCd + Not tested 4×105 2 
6 Pneumonia M, 64 Collagen disease CTRXe － － 1×105 6 
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TABLE 5. Comparison of clinical and laboratory data between ODK0501+ and Binax 




Binax NOW (+) 
(n = 30) 
ODK0501(+) 
and 
Binax NOW (-) 
(n = 15) 
P 
Age, median years (range) 67 (22-86) 72 (34-84) 0.718 
Male gender 21 (70.0) 14 (93.3) 0.129 
Final diagnosis    
 Pneumonia 28 (93.3) 12 (80.0) 0.315 
 Bronchiectasis 1 (3.3) 0 (0.0) 1 
 Acute exacerbation of COPD 1 (3.3) 1 (6.7) 1 
 Acute bronchitis 0 (0.0) 1 (6.7) 1 
 Chronic bronchitis 0 (0.0) 1 (6.7) 1 
Underlying disease＊ 18 (60.0) 10 (66.7) 0.752 
 COPD 5 (16.7) 8 (53.3) 0.016 
 Diabetes 3 (10.0) 1 (6.7) 1 
 Chronic lung disease 0 (0.0) 0 (0.0) 1 
 Chronic heart disease 1 (3.3) 0 (0.0) 1 
 Chronic liver disease 1 (3.3) 0 (0.0) 1 
 Chronic renal insufficiency 0 (0.0) 0 (0.0) 1 
 Cancer 2 (6.7) 1 (6.7) 1 
 Dementia 0 (0.0) 0 (0.0) 1 
Prior antibiotic therapy 5 (16.7) 0 (0.0) 0.153 
CRP, average (range) (mg/dl) 14 (0.3-31.5) 11 (2.0-24.0) 0.448 
WBC, average (range) (/mm3) 12,224 13,723 0.754 
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(2,800-31,700) (6,800-48,800) 







Time from onset of symptoms until assay 
(days) (range) 
4 (0-10) 2 (0-9) 0.420 
COPD, Chronic obstructive pulmonary disease; Data are ratios (%) of patients, unless otherwise 




FIG. 1. Distribution of S. pneumoniae Psp A gene copy number in sputum compared 
among ODK0501- and culture positive and -negative populations. 
Vertical axis, copy number of Psp A gene calculated from real-time PCR. ●, S. 
pneumoniae culture-negative; ○, S. pneumoniae culture-positive. ODK0501-positive 
and culture-positive populations contain more copies of S. pneumoniae Psp A gene. 
Copy numbers significantly differed between ODK0501-positive and -negative 
populations (P < 0.001). 
